AGTR1 and myocardial infarction: Despite significant progress in recently FDA approved drugs, such as inhibitors of angiotensin converting enzyme, blockers of an adrenergic receptor and angiotensin II type 1 receptor (AT1R), MI remains a deadly clinical problem [10].